查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401172

用於細胞和基因治療的藥物輸送裝置的全球市場：市場規模、佔有率、趨勢分析、機會和預測（2019-2029）

Cell and Gene Therapy Drug Delivery Devices Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product Type ; By Technology ; By Commercialized Drug ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球細胞和基因療法藥物輸送設備市場規模預計在預測期內將增加一倍以上，到 2029 年將達到 253,700 美元。

由於專注於開發有效的治療方法和輸送設備來治療和管理越來越多的慢性疾病，用於細胞和基因治療的藥物傳輸設備的全球市場正在蓬勃發展。

在最近的一項研究中，領先的策略諮詢和市場研究公司 BlueWeave Consulting 預計 2022 年細胞和基因治療藥物輸送市場規模將達到 99,970 美元。 BlueWeave估計，在2023-2029年的預測期內，用於細胞和基因治療的藥物輸送設備的全球市場規模預計將以16.79%的複合年成長率顯著成長，並於2029年達到253,690美元。全球細胞和基因治療藥物傳輸市場的主要成長動力是癌症和慢性病盛行率的增加、該領域投資的增加、對罕見疾病治療方法創新的需求，其中包括藥品研發成本的增加以及FDA核准和臨床試驗的數量增加。已經出現了幾種基於細胞和基因的治療方法，它們利用生物工程技術來增強免疫系統抵抗疾病的能力，同時維持周圍組織的健康。例如，基於抗體的治療方法可以透過加強 T 細胞與癌細胞的相互作用來提高 T 細胞的有效性。其他改進，例如增加 CAR-T 與癌細胞之間相互作用的複雜性，將有助於提高 T 細胞靶向癌症的能力並減少對正常細胞的傷害。人口高齡化的加劇，加上全球癌症和遺傳疾病發生率的增加，預計將顯著增加細胞和基因治療市場對藥物傳遞設備的需求。該公司在細胞和基因療法以及相關藥物輸送設備的研發方面進行的大量投資也證明了該行業對進步的承諾。近年來各種遺傳和慢性疾病臨床試驗的成長趨勢預計將在預測期內推動細胞和基因治療藥物傳輸設備市場。然而，製造系統的高成本和缺乏標準處理方案預計將限制預測期內的整體市場成長。

機會－增加細胞和基因治療的研發投資

細胞和基因治療市場正在見證私人和公共投資的大量湧入。對治療不足的病理進行創新治療方法的吸引力正在透過私人投資、首次股票公開發行和企業資金籌措吸引大量資金。私人公司增加對生命科學研究和開發的投資有助於細胞和基因治療資金的快速成長。值得注意的是，2010年至2021年基因治療和細胞治療的投資成長率分別為59%和63%，在預測期內對推動全球細胞和基因治療藥物輸送設備市場發揮了關鍵作用。此外，各地區政府正在積極提高患者和醫療保健專業人員的意識，進一步推動全球細胞和基因治療藥物傳輸設備市場的成長。

COVID-19 對細胞和基因治療藥物輸送設備全球市場的影響

COVID-19 大流行對全球細胞和基因治療藥物輸送市場產生了負面影響。有多種因素導致了這種情況的惡化，包括製造和物流流程的中斷，導致材料供應鏈變得非常複雜。大流行促使各臨床中心暫停業務，以降低病毒暴露的風險。對於保存期限短、需要在製造地和給藥中心之間及時運輸的細胞治療藥物來說，出貨延誤是一個挑戰。儘管存在這些障礙，市場參與者仍將重點轉向應對大流行相關的挑戰，基因治療公司積極參與 COVID-19 疫苗的研究和生產。這一轉變導致了競爭非專利藥（CGT）定價和報銷的顯著擴展。

細胞和基因治療藥物傳遞的全球市場 - 按成藥

全球細胞和基因治療藥物輸送市場按成藥細分為 Luxturna、Kymriah、Yescarta、Zolgensma、Provenge 和 Strimvelis 部分。 Luxturna 部門在全球細胞和基因治療藥物傳輸設備市場上擁有最高的商業化藥物佔有率。以voretigene neparvovec-rzyl為代表的Luxturna是一種開創性的基因療法，可直接針對導致視網膜營養不良的特定基因突變。它是第一個在美國核准直接給藥的基因療法藥物，專注於治療與已確定的雙基因 RPE65 突變相關的視網膜營養不良。 Luxturna 的機制涉及使用改良的腺結合病毒作為載體，將 RPE65 基因的功能副本直接傳遞到視網膜細胞。這種創新方法可以恢復正常的蛋白質生產，並將光轉化為視網膜中的電訊號，有效防止視力喪失。由於其突破性的特性以及在治療某些遺傳疾病方面的成功，Luxturna 引起了人們的關注，並在細胞和基因治療藥物輸送設備市場佔據了重要佔有率。

全球細胞和基因治療藥物傳輸市場（按地區）

全球細胞和基因治療藥物遞送市場的詳細研究報告涵蓋了北美、歐洲、亞太、拉丁美洲、中東和非洲五個關鍵地區的眾多主要國家的市場。在該區域。北美地區在細胞和基因治療藥物傳遞的全球市場中佔據最高佔有率。該地區的主導地位是由於各種中小企業和大型企業集團之間不斷加強合作，旨在開發價格實惠的優質藥品。此外，神經退化性疾病的增加以及透過研究、診斷和合成生物學尋找遺傳性疾病有效治療方法的需求不斷成長，也對該地區的市場成長做出了重大貢獻。在該地區，美國預計將在預測年內呈現最快的市場成長。這是由於監管機構，例如在該國營運的生技藥品評估與研究中心（CBER），專注於細胞和基因治療的藥物傳輸設備。 CBER 為研究人員和製造商的新產品開發提供科學和監管指導。

競爭形勢

在全球細胞和基因治療藥物輸送設備市場中運作的一些主要企業包括 Amgen Inc.、Bausch &Lomb Incorporated、Renova Therapeutics、Becton、Dickinson and Company、Bluebird bio-Inc.、Castle Creek Biosciences, Inc.、Helixmith Co. Ltd 、Kite Pharma Inc.、Kolon TissueGene, Inc.、Novartis AG、Orchard Therapeutics plc.、Pfizer Inc.。為了進一步增加市場佔有率，這些公司正在尋求併購、合作、合資和許可協議。,並採取各種策略，例如新產品發布。

該報告的詳細分析提供了有關全球細胞和基因治療藥物輸送市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告承諾提供全球細胞和基因治療藥物輸送市場的最新技術趨勢以及行業見解，以幫助決策者做出適當的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章 全球細胞與基因治療藥物傳遞設備的市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 慢性病盛行率增加
      • 臨床試驗數量增加
    • 抑制因素
      • 高成本製造系統
      • 缺乏標準治療方案
    • 機會
      • 提高患者和醫生的設備意識
      • 細胞和基因治療投資快速成長
    • 任務
      • 缺乏熟練的專業人員
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章細胞和基因治療藥物輸送裝置的全球市場概述

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
      • 視網膜下注射插管
      • 延長管
      • 靜脈導管
      • 無菌胰島素注射器
      • 預充式注射器
      • 點滴袋
    • 依技術
      • 微晶片技術
      • 奈米科技
      • 脂質奈米粒子
    • 透過成藥
      • Luxturna
      • Kymriah
      • Yescarta
      • Zolgensma
      • Provenge
      • Strimvelis
    • 按最終用戶
      • 製藥和生物技術公司
      • 學術/研究機構
      • 醫院/診所
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章北美細胞與基因治療藥物傳遞設備市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
    • 依技術
    • 透過成藥
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第6章歐洲細胞與基因治療藥物傳遞設備市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
    • 依技術
    • 透過成藥
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 歐洲其他地區

第7章亞太細胞與基因治療藥物傳遞設備市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
    • 依技術
    • 透過成藥
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲/紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第8章拉丁美洲細胞與基因治療藥物傳輸設備市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
    • 依技術
    • 透過成藥
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第9章中東和非洲細胞和基因治療藥物傳輸設備市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 依產品類型
    • 依技術
    • 透過成藥
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第10章競爭形勢

  • 主要企業及其產品列表
  • 2022年全球細胞與基因治療藥物傳遞設備市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）
簡介目錄
Product Code: BWC231042

Global Cell and Gene Therapy Drug Delivery Devices Market Size More Than Doubles During Forecast Period to Touch USD 253.7 Thousand by 2029

Global Cell and Gene Therapy Drug Delivery Devices Market is flourishing because of a growing focus on developing efficient therapies and delivery devices for the treatment and management of the increasing prevalence of chronic diseases.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Cell and Gene Therapy Drug Delivery Devices Market size at USD 99.97 thousand in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Cell and Gene Therapy Drug Delivery Devices Market size to grow at a significant CAGR of 16.79% reaching a value of USD 253.69 thousand by 2029. Major growth drivers for the Global Cell and Gene Therapy Drug Delivery Devices Market include an increasing prevalence of cancer and chronic diseases, increasing investments in the sector, the imperative to innovate treatments for rare diseases, augmented research and development expenditure in biopharmaceuticals, and a rising number of FDA approvals and clinical trials. Several emerging approaches in cell and gene-based therapies leverage biological engineering to enhance the immune system's ability to combat diseases while preserving the health of surrounding tissues. For instance, antibody-based therapies can enhance the effectiveness of T-cells by intensifying their interactions with cancer cells. Other modifications, such as enhancing the complexity of CAR-T and cancer cell interactions, contribute to refining T-cells' ability to target cancer, thereby reducing harm to normal cells. The escalating aging population, coupled with a growing incidence of cancer cases and genetic disorders globally, is projected to result in a significantly increased demand for drug delivery devices within the cell and gene therapy market. Also, substantial investments by companies in the research and development of cell and gene therapies, along with associated drug delivery devices, underscore the industry's commitment to advancements. The upward trajectory of clinical trials for various genetic and chronic diseases in recent years is poised to propel the cell and gene therapy drug delivery devices market during the forecast period. However, high cost of manufacturing system and lack of standard therapy protocols are anticipated to restrain the overall market growth during the forecast period.

Opportunity - Increasing Investments in Cell Therapy and Gene Therapy R&D

The cell therapy and gene therapy market is witnessing a notable influx of both private and public investment. The appeal of innovative therapies addressing underserved medical conditions has attracted substantial capital through private investments, initial public offerings, and corporate funding. The increasing amount of investments by private players in life sciences R&D is contributing to the rapid growth in funding for cell therapy and gene therapy. Notably, the investment growth rates for gene therapy and cell therapy from 2010 to 2021 are 59% and 63%, respectively, indicating a significant role in advancing the global Cell & Gene Therapy Drug Delivery Devices Market during the forecast period. Additionally, various governments across the regions are actively promoting awareness among patients and healthcare professionals, further fostering the growth of the Global Cell & Gene Therapy Drug Delivery Devices Market.

Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market

COVID-19 pandemic adversely affected the Global Cell and Gene Therapy Drug Delivery Devices Market. Several factors contributed to this exacerbation, including disruptions in manufacturing and logistics processes, leading to significant complexities in the supply chain of materials. The pandemic prompted the suspension of operations at various clinical centers to mitigate the risk of virus exposure. Shipment delays posed challenges for cell therapies with short shelf lives, requiring timely transportation between manufacturing sites and administration centers. Despite these obstacles, market players shifted their focus to addressing pandemic-related challenges, with gene therapy companies actively engaging in COVID-19 vaccine research and manufacturing. This pivot resulted in significant expansions in prices and reimbursements for Competitive Generic Therapy (CGTs).

Global Cell and Gene Therapy Drug Delivery Devices Market - By Commercialized Drugs

Based on commercialized drugs, the Global Cell and Gene Therapy Drug Delivery Devices Market is divided into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis segments. The Luxturna segment holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market by commercialized drugs. Luxturna, represented by voretigene neparvovec-rzyl, is a pioneering gene therapy that directly addresses specific genetic mutations causing retinal dystrophy. It stands out as the first gene therapy approved in the United States for direct administration, focusing on treating confirmed biallelic RPE65 mutation-associated retinal dystrophy. Luxturna's mechanism involves delivering a functional copy of the RPE65 gene directly to retinal cells, utilizing a modified adeno-associated virus as a vector. This innovative approach restores the normal protein production, converting light into electrical signals in the retina and effectively addressing vision loss. Due to its groundbreaking nature and successful outcomes in treating a specific genetic disorder, Luxturna has gained prominence and secured a significant share in the market for cell and gene therapy drug delivery devices.

Global Cell and Gene Therapy Drug Delivery Devices Market - By Region

The in-depth research report on the Global Cell and Gene Therapy Drug Delivery Devices Market covers the market in a number of key countries across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market. The region's dominance is attributed to the increasing collaborations between various small and medium enterprises and large conglomerates, aiming to develop affordable and high-quality medicines. Also, the rising occurrences of neurodegenerative issues and the growing demand for finding effective treatments for gene disorders through research, diagnostics, and synthetic biology are significant contributors to the regional market's growth. Within the region, the United States is expected to exhibit the fastest market growth in the forecast years. This is attributed to regulatory bodies like the Centre for Biologics Evaluation & Research (CBER) operating in the country, focusing on cell and gene therapy devices. The CBER provides scientific and regulatory guidance to researchers and manufacturers for the development of new products.

Competitive Landscape

Major players operating in the Global Cell and Gene Therapy Drug Delivery Devices Market include Amgen Inc., Bausch & Lomb Incorporated, Renova Therapeutics, Becton, Dickinson and Company, Bluebird bio-Inc., Castle Creek Biosciences, Inc., Helixmith Co. Ltd, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., and Pfizer Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Cell and Gene Therapy Drug Delivery Devices Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Cell and Gene Therapy Drug Delivery Devices Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Cell and Gene Therapy Drug Delivery Devices Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Rising number of clinical trials
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of manufacturing system
      • 3.2.2.2. Lack of standard therapy protocols
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing awareness about the devices among patients and doctors
      • 3.2.3.2. Rapid growth in investment in cell therapy and gene therapy
    • 3.2.4. Challenges
      • 3.2.4.1. Shortage of skilled professionals
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Cell and Gene Therapy Drug Delivery Devices Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Thousand)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Product Type
      • 4.2.1.1. Subretinal Injection Cannula
      • 4.2.1.2. Extension Tube
      • 4.2.1.3. Intravenous Catheter
      • 4.2.1.4. Sterile Insulin Syringe
      • 4.2.1.5. Pre-Filled Syringe
      • 4.2.1.6. Infusion Bags
    • 4.2.2. By Technology
      • 4.2.2.1. Microchip Technology
      • 4.2.2.2. Nanotechnology
      • 4.2.2.3. Lipid Nanoparticles
    • 4.2.3. By Commercialized Drugs
      • 4.2.3.1. Luxturna
      • 4.2.3.2. Kymriah
      • 4.2.3.3. Yescarta
      • 4.2.3.4. Zolgensma
      • 4.2.3.5. Provenge
      • 4.2.3.6. Strimvelis
    • 4.2.4. By End User
      • 4.2.4.1. Pharmaceuticals & Biotechnology Company
      • 4.2.4.2. Academic & Research Institute
      • 4.2.4.3. Hospitals & Clinics
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Cell and Gene Therapy Drug Delivery Devices Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Thousand)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Technology
    • 5.2.3. By Commercialized Drugs
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Product Type
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Commercialized Drugs
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product Type
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Commercialized Drugs
      • 5.2.5.2.4. By End User

6. Europe Cell and Gene Therapy Drug Delivery Devices Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Thousand)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Commercialized Drugs
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product Type
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Commercialized Drugs
      • 6.2.5.1.4. By End User
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Product Type
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Commercialized Drugs
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product Type
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Commercialized Drugs
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product Type
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Commercialized Drugs
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product Type
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Commercialized Drugs
      • 6.2.5.5.4. By End User
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Product Type
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Commercialized Drugs
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Product Type
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Commercialized Drugs
      • 6.2.5.7.4. By End User
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Product Type
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Commercialized Drugs
      • 6.2.5.8.4. By End User
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Product Type
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Commercialized Drugs
      • 6.2.5.9.4. By End User

7. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Thousand)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Commercialized Drugs
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product Type
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Commercialized Drugs
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product Type
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Commercialized Drugs
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product Type
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Commercialized Drugs
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product Type
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Commercialized Drugs
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product Type
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Commercialized Drugs
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product Type
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Commercialized Drugs
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product Type
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Commercialized Drugs
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product Type
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Commercialized Drugs
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Product Type
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Commercialized Drugs
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Product Type
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Commercialized Drugs
      • 7.2.5.10.4. By End User

8. Latin America Cell and Gene Therapy Drug Delivery Devices Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Thousand)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Commercialized Drugs
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product Type
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Commercialized Drugs
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product Type
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Commercialized Drugs
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product Type
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Commercialized Drugs
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product Type
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Commercialized Drugs
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product Type
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Commercialized Drugs
      • 8.2.5.5.4. By End User

9. Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Thousand)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Commercialized Drugs
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product Type
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Commercialized Drugs
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product Type
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Commercialized Drugs
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product Type
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Commercialized Drugs
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product Type
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Commercialized Drugs
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product Type
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Commercialized Drugs
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product Type
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Commercialized Drugs
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product Type
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Commercialized Drugs
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product Type
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Commercialized Drugs
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Cell and Gene Therapy Drug Delivery Devices Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)